**Abstract**

Doxycycline (4,5,5,6,12)-4-(dimethylamino)-3,5,10,12,12-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydotetracene-2-carboxamide) is a drug used for the treatment of infections caused by bacteria and protozoa. We carried out molecular docking for six analogous structurally diverse (doxycycline) against *Pseudomonas aeruginosa* lipase using Patchdock and Firedock softwares server. Extensive structure activity relationship work was carried out with these molecules. Physicochemical, lipophilicity, solubility, pharmacokinetics and Lipinski druglikeness of doxycycline and its analogues were evaluated. These molecules were designed by substituting NH with NO₂, CONH₂, COOH, CHO and OCH₃ functional groups. The scoring function (empirical binding free energy) was used to estimate the inhibitory activity of protein-ligand complex. The binding energy of doxycycline was -39.25kcal/mol. The free binding energies of NO₂, CHO, CONH₂, COOH, and OCH₃, analogues of doxycycline were -43.43, -43.86, -44.97, -39.40 and -35.78kcal/mol respectively. All the monosubstituted analogues of doxycycline, except COOH monosubstituted analogue showed lower values than the non substituted doxycycline. These lower values (more negative values), means that they show better antimicrobial activity than doxycycline. These results clearly indicated that the new substituents may be better antimicrobial agents. Synthesis and pre-clinical studies of these monosubstituted derivatives with *Pseudomonas aeruginosa* lipase is recommended in order to confirm their new potentials as better antimicrobial agent than the unsubstituted analogue.

**Keywords:** Docking; Doxycycline; *Pseudomonas aeruginosa* lipase; Scoring function; Solubility

**Abbreviations:** PDB: Protein Data Bank; BBB: Blood Brain Barrier; NO₂: Nitrogen Dioxide; COOH: Carboxylic Acid

**Introduction**

One of the important drugs used for the treatment of infections caused by bacteria and protozoa is doxycycline. It is indicated for lung infection of bacterial origin, chlamydia, syphilis and chola. It has also been used in combination with quinine for prevention of malaria [1]. Doxycycline is a broad spectrum antibiotic belonging to the class of tetracycline which its anti microbial activity is by inhibition of protein biosynthesis [1,2]. It became an important medication needed in basic health care delivery in man and animals [3].

*Moraxella catarrhalis, Chlamydia pneumoniae, Mycoplasma pneumoniae* and *Brucella melitensis* are generally susceptible to doxycycline, while some *Mycoplasma hominis, Pseudomonas aeruginosa* and *Haemophilus spp* have developed resistance to varying degrees [4]. Doxycycline is used in the treatment of respiratory tract infection [5], lyme disease [6-10], psittacosis, relapsing fever, chancroid, chola, campylobacter fetus infections, brucellosis, bubonic plague, Rocky mountain spotted fever and ehrlichiosis while being used for prophylaxis and treatment of leptospirosis [11] and Anthrax [12,13]. Some Gram-positive bacteria have developed resistance to Doxycycline except *Streptococcus pneumonia*, *Staphylococcus aureus* and *Bacillus anthracis* while some infections caused by Gram-negative bacteria can be treated by Doxycycline such as *Shigella* species infections, *Enterobacter* aerogenes infections, *Escherichia coli*, *Actinobacter* species infections, *Haemophilus influenza* infections and *Klebsiella* species infections [14,15]. Doxycycline has been successfully used to treat respiratory tract infection, ophthalmic and sexually transmitted diseases. Adverse effects have been seen to include erythematous rash in sun exposed parts of the body which resolves on the discontinuation of the drug [16].

Interaction of doxycycline with food and drugs containing antacids, dairy products, iron, magnesium and calcium supplements reduces doxycycline absorption and effectiveness [17] probably due to chelation and an increased gastric pH making it advisable for doxycycline to be taken on an empty stomach [18]. Doxycycline is contraindicated during pregnancy, breastfeeding, infancy and childhood stages in humans because it crosses into breastmilk and disrupts bone and tooth development in these stages up to the age of eight years [19,20] except in the treatment of anthrax where other medications are not effective [14]. The mechanism of action of the antibacterial effect of tetracyclines
relies on disrupting protein translation in bacteria, thereby damaging the ability of microbes to grow and repair; however protein translation is also disrupted in eukaryotic mitochondria impairing metabolism and leading to effects that can confound experimental results [21,22].

Drugs are observing resistance to microbes due to long use. We are docking the doxycycline with monosubstituated compounds to check if they will have better activity and probably show no resistance to microbes. The aim for this research is to determine the substituents that will improve the activity of doxycycline as an antibacterial and anti-protozoa drug and recommend these monosubstituted derivatives for synthesis and pre-clinical trials. Doxycycline structural formula is shown in Figure 1.

![Doxycycline structural formula](image1)

**Materials and Methods**

**Protein preparation**

The crystal structure of *Pseudomonas aeruginosa lipase*, was obtained from the Protein Data Bank, PDB 1ex9 (Figure 2). The protein structure was subjected to a refinement protocol using Molegro molecular viewer [23].

**Designing of structural analogues of doxycycline**

The structure of doxycycline (Figure 1a) was drawn with ACD/ChemSketch software [24]. The structural analogues of doxycycline were developed with structural modifications with different substituents. The NH$_2$ group of doxycycline was replaced with CHO, NO$_2$, CONH$_2$, COOH, and OCH$_3$ analogues. The structures were built with ACD/ChemSketch software and minimized with Arguslab software [25].

**Molecular docking**

Molecular docking was performed using Patchdock software server [26]. Patchdock is a molecular docking algorithm based on shape complementarity principles. Refinement was done with FireDock server [27,28] and processed with Molegro molecular viewer. Physicochemical, lipophilicity, solubility, pharmacokinetics and Lipinski druglikeness of doxycycline and its analogues were determined using SwissADME Server [29].

**Results and Discussion**

The physicochemical, lipophilicity, solubility, pharmacokinetics and Lipinski druglikeness of doxycycline and its analogues are shown in Table 1. Crystal structure of *Pseudomonas aeruginosa lipase*, is shown in Figure 2, while the docked Doxycycline analogues with *Pseudomonas aeruginosa lipase*, are presented in Figures 3-8. The bonding interactions are depicted in Figures 9-14.

![Crystal structure of *Pseudomonas aeruginosa lipase* PDB 1ex9](image2)

**Table 1: Physicochemical, lipophilicity, solubility, pharmacokinetics and Lipinski druglikeness of doxycycline and its analogues.**

| Parameters                          | Doxycycline | NO$_2$ Analogue of Doxycycline | CHO Analogue of Doxycycline | CONH$_2$ Analogue of Doxycycline | COOH Analogue of Doxycycline | OCH$_3$ Analogue of Doxycycline |
|-------------------------------------|-------------|---------------------------------|-----------------------------|----------------------------------|------------------------------|---------------------------------|
| Docking score Kcal/mol              | -39.25      | -43.43                          | -43.86                      | -44.97                           | -39.4                        | -35.78                          |
| Num. H-bond acceptors              | 9           | 11                              | 10                          | 10                               | 11                           | 10                              |
| Num. H-bond donors                 | 6           | 5                               | 5                           | 6                                | 6                            | 5                               |
| Molar Refractivity                 | 110.91      | 116.3                           | 113.21                      | 115.91                           | 114.78                       | 114.09                          |
| Lipophilicity Consensus Log $P_{ow}$ | -0.15       | -0.12                           | -0.05                       | -0.76                            | -0.57                        | 0.28                            |
| Water Solubility Class             | Soluble     | Soluble                         | Soluble                     | Soluble                          | Very soluble                 | Soluble                         |
| GI absorption                      | Low         | Low                             | Low                         | Low                              | Low                          | Low                             |
| BBB permeant                       | No          | No                              | No                          | No                               | No                           | No                              |
| P-gp substrate                     | Yes         | Yes                             | Yes                         | Yes                              | No                           | Yes                             |
| CYP1A2 inhibitor                   | No          | No                              | No                          | No                               | No                           | No                              |

![Doxycycline structural formula](image1)

![Crystal structure of *Pseudomonas aeruginosa lipase* PDB 1ex9](image2)

**Citation:** Ikpeazu OV, Otuokere IE, Igwe KK (2017) *In Silico Structure-Activity Relationship and Virtual Screening of Monosubstituted Doxycycline with Pseudomonas Aeruginosa Lipase.* J Anal Pharm Res 5(3): 00139. DOI: 10.15406/japlr.2017.05.00139
| CYP2C19 inhibitor | No | No | No | No | No | No | No |
| CYP2C9 inhibitor  | No | Yes | No | No | No | No | No |
| CYP2D6 inhibitor  | No | No | No | No | No | No | No |
| CYP3A4 inhibitor  | No | No | No | No | No | No | No |
| Lipinski Druglikeness | Yes; 1 violation: H-don>5 | Yes; 1 violation: H-acc>10 | Yes; 0 violation | Yes; 1 violation: H-don>5 | No; 2 violations: H-acc>10, H-don>5 | Yes; 0 violation |
| Synthetic accessibility | 5.15 | 5.28 | 5.1 | 5.2 | 5.15 | 5.21 |

**Figure 3:** NO₂ analogue of doxycycline in complex with *Pseudomonas aeruginosa* lipase.

**Figure 4:** CHO analogue of doxycycline in complex with *Pseudomonas aeruginosa* lipase.

**Figure 5:** CONH₂ analogue of doxycycline in complex with *Pseudomonas aeruginosa* lipase.

**Figure 6:** COOH analogue of doxycycline in complex with *Pseudomonas aeruginosa* lipase.

**Figure 7:** OCH₃ analogue of doxycycline in complex with *Pseudomonas aeruginosa* lipase.

**Figure 8:** Doxycycline in complex with *Pseudomonas aeruginosa* lipase.

**Figure 9:** Steric interaction of NO₂ doxycycline analogue with amino acids residue of *Pseudomonas aeruginosa* lipase.

**Figure 10:** COOH analogue of doxycycline in complex with *Pseudomonas aeruginosa* lipase.
the compounds showed that they bind in a very similar pattern with the active site of *Pseudomonas aeruginosa lipase*, as is evident from the superposition of all the 6 analogues in Figures 3-8. The interaction between different substituted analogues with *Pseudomonas aeruginosa lipase* shows steric interactions with amino acids residues. The calculated free energy of binding of the 6 doxycycline analogues were -39.25, -43.43, -43.86, -44.97, 39.40 and -35.78 Kcal/mol (Table 1). This confirms that the structural modification implemented in this study is significantly related to their activity. Also, this proved the reasonability and reliability of the docking results. It can be seen that substitution of NH$_2$ functional group of doxycycline with CHO, NO$_2$, CONH$_2$, and COOH analogues lead to an increase in the binding affinity of modified analogues which is even more intense than that of doxycycline. The binding energy of doxycycline was -39.25 Kcal/mol.

Solubility of compounds in water could improve its biotransformation and elimination as a drug. All the substituted analogues were soluble in water (Table 1). All the substituted derivatives were less than 500 Daltons in mass showing that they can be considered as drug. High lipophilicity which is expressed as Log $P_{o/w}$ less than 5 is considered to have drug likeness. All the substituted compounds had 0.28-0.76 (less than 5) and were most likely to be drugs. In the violation of Lipinski rule, a violation of only one of the 5 rules is acceptable for a drug. All the substituted analogues showed favorable Lipinski rule except the aldehyde [CHO] substituted analogue that violated two rules; less than 5 hydrogen bond donor; less than 10 hydrogen bond acceptors. Therefore the CHO analogues is not likely to be a drug though it is very soluble in water. Lipinski rule of 5 [30] helps in distinguishing between drug like and non-drug like molecules. It predicts high probability of success or failure due to drug likeness for molecules complying with 2 or more of the following rules: Molecular mass less than 500 Dalton; High lipophilicity (expressed as Log $P_{o/w}$ less than 5); Less than 5 hydrogen bond donors; Less than 10 hydrogen bond acceptors; Molar refractivity should be between 40-130. These filters help in early preclinical development and could help avoid costly late-stage preclinical and clinical failures.

Pharmacokinetically, the gastrointestinal drug absorption of all the substituents was low and they could not cross the blood brain barrier (BBB) showing that they cannot cause problem to the brain. For synthetic accessibility, values of 5 to 10 means that the drug could be synthesized. All the substituted analogues could be synthesized in the laboratory because they range between 5.10 and 5.21.

These results clearly indicated that before synthesis and biochemical testing of new analogues one can use molecular docking based methods for qualitative assessment of relative binding affinities for speeding up drug discovery process by eliminating less potent compounds from synthesis. Synthetic studies followed by pre-clinical studies are further recommended.

**Conclusion**

We carried out molecular docking for six analogous structurally diverse doxycycline with *Pseudomonas aeruginosa lipase* using Patchdock and Firedock softwares servers. The binding energy of doxycycline was -39.25 Kcal/mol. The NO$_2$, CONH$_2$, and COOH structural analogues were found to be lower (more negative)
In Silico Structure-Activity Relationship and Virtual Screening of Monosubstituted Doxycycline with Pseudomonas Aeruginosa Lipase

Acknowledgement

We are grateful for the research grant from Abia State Government, Nigeria.

References

1. https://www.drugs.com/monograph/doxycycline-calcium.html
2. Nelson ML, Levy SB (2011) The history of the tetracyclines. Ann N Y Acad Sci 1241: 17-32.
3. http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf
4. https://www.drugs.com/pm/doxycycline.html
5. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, et al. (2012) Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 55(12): 1642-1649.
6. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, et al. (1992) Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 117(4): 273-280.
7. Luger SW, Paparone SP, Wormser GP (1995) Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 39(3): 661-667.
8. Nadelman RB, J. Nowakowski, Fish JD (2001) "Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. The New England Journal of Medicine 345(2): 79-84.
9. Karlsson M, Hammers-Berggren S, Lindquist L, Sternstedt G, Svennungsson B (1994) Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 44(7): 1203-1207.
10. https://www.lyme-disease.org/lyme-basics/lyme-disease/treatment/
11. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/leptospirosis.htm
12. Weinstein RS (1996) Human ehrlichiosis. Am Fam Physician 54(6): 1971-1976.
13. Karlsson N, Björsorff A, Massung RF, Christensson B (2001) Human granulocytic ehrlichiosis-a clinical case in Scandinavia. Scand J Infect Dis 33(1): 73-74.
14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/065454s000lbl.pdf
15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/065454s000lbl.pdf
16. Katherine R Tan, Alan J. Magill, Monica E Parise, Paul M Arguin (2012) Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis. The American Journal of Tropical Medicine and Hygiene 84(4): 517-531.
17. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0010039/?report=details
18. Khursagar NA, Ankalesari PS (1987) Effect of food on doxycycline absorption. J Postgrad Med 33(3): 117-119.
19. Mylonas I (2011) Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Arch Gynecol Obstet 283(1): 7-18.
20. Chun AM, Reed MD, Blume JL (2002) Antibiotics and breast-feeding: a critical review of the literature. Paediatr drugs 4(12): 817-837.
21. Moullin N, Mouchiroud L, Wang X, Ryu D, Williams EG, et al. (2015) Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. Cell Rep 10(10): 1681-1691.
22. Chatzizyprou IA, Held NM, Mouchiroud L, Auwerx J, Houtkooper RH (2015) Tetracycline antibiotics impair mitochondrial function and its experimental use confounds research. Cancer Research 72(21): 4446-4449.
23. http://www.clcbio.com
24. http://www.acdlabs.com
25. http://www.arguslab.com
26. Duhovny D, Nussinov R, Wolfson HJ (2002) Efficient Unbound Docking of Rigid Molecules. International Workshop on Algorithms in Bioinformatics 2452: 185-200.
27. Mashiach E, Schneider-Duhovny D, Andrusier N, Nussinov R, Wolfson HJ (2000) FireDock a webserver for fast interaction refinement in molecular docking. Nucleic Acids Res 36: 229-292.
28. Andrusier N, Nussinov R, Wolfson HJ (2007) FireDock: fast interaction refinement in molecular docking. Proteins 69(1): 139-159.
29. Daina A, Michielin O, Zoete V (2017) A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7: 42717.
30. Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies 1(4): 337-341.
31. Anna KC, Bruce MN (1994) Investigations into the Chemistry of Thermodynamically Unstable Species. The Direct Polymerization of Vinyl Alcohol, the Enolic Tautomer of Acetaldehyde. JACS 116: 4073-4074.

Citation: Ikpeazu OV, Otuokere IE, Igwe KK (2017) In Silico Structure-Activity Relationship and Virtual Screening of Monosubstituted Doxycycline with Pseudomonas Aeruginosa Lipase. J Anal Pharm Res 5(3): 00139. DOI: 10.15406/japlr.2017.05.00139